DEXACORT Drug Patent Profile
When do Dexacort patents expire, and what generic alternatives are available?
Dexacort is a drug marketed by Ucb Inc and is included in two NDAs.
The generic ingredient in DEXACORT is dexamethasone sodium phosphate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the dexamethasone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dexacort
A generic version of DEXACORT was approved as dexamethasone sodium phosphate by HIKMA on September 7th, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DEXACORT?
- What are the global sales for DEXACORT?
- What is Average Wholesale Price for DEXACORT?
Summary for DEXACORT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,703 |
| DailyMed Link: | DEXACORT at DailyMed |
Recent Clinical Trials for DEXACORT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tel-Aviv Sourasky Medical Center | N/A |
US Patents and Regulatory Information for DEXACORT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | DEXACORT | dexamethasone sodium phosphate | AEROSOL, METERED;INHALATION | 013413-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ucb Inc | DEXACORT | dexamethasone sodium phosphate | AEROSOL;NASAL | 014242-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

